Objective: To perform a systematic review and meta-analysis comparing doublet versus single agent therapy in elderly patients with advanced nonsmall-cell lung cancer (NSCLC). were searched. Endpoints were overall survival (OS), 1-year survival rate (1-year SR), overall response rate (ORR), and grade 3/4 adverse events. Subgroup analyses were based on chemotherapy regimens and race. Results: Out of 11 studies (13 randomized trials; n ¼ 2782), doublet therapy was associated with significantly increased OS (hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.83, 0.95), 1-year SR (risk ratio [RR] 1.15, 95% CI 1.04, 1.28), and ORR (RR 1.39, 95% CI 1.39, 1.86) versus singleagents. Chemotherapy regimen-based subgroup analyses favoured platinum-based doublet therapy for OS (RR 0.71, 95% CI 0.60, 0.84), 1-year SR (RR 1.28, 95% CI 1.11, 1.47), and ORR (RR 1.88, 95% CI 1.49, 2.38). Race-based subgroup analyses revealed increased benefit from doublet therapy in Asian populations for ORR (RR 1.70, 95% CI 1.29, 2.23) but not increased survival benefit. Higher incidences of grade 3/4 anaemia (RR 2.23, 95% CI 1.61, 3.09), thrombocytopenia (RR 2.47, 95% CI 1.17, 5.20), and fatigue (RR 1.36, 95% CI 1.06, 1.74) were observed with doublet versus single-agent therapy. Conclusions: Doublet therapy was associated with significantly increased OS, 1-year SR and ORR compared with single agent therapy. Race may be considered when choosing doublet versus singleagent therapy as first-line treatment of NSCLC in elderly patients.
Introduction
Lung cancer is the leading cause of cancerrelated death worldwide. Increasing life expectancy, with its concomitant increased cancer risk, has led to a significant increase in incidence of lung cancer in older people and represents a major societal disease burden. [1] [2] [3] [4] Clinical trials of doublet therapies in elderly patients with advanced nonsmallcell lung cancer (NSCLC) have reported survival benefits compared with monotherapy. The Southern Italy Cooperative Oncology Group trial, which compared gemcitabine plus vinorelbine versus vinorelbine alone in 152 patients aged 70 years, found that combination therapy improved overall median survival from 18 to 29 weeks. 5 Another published trial comparing gemcitabine and carboplatin with gemcitabine monotherapy in NSCLC patients (median age, 79 years) found improved survival benefits in the doublet arm (overall survival [OS] increased from 12.6 to 15.4 months; progression-free survival increased from 2.4 to 3.9 months). 6 Conversely, the Multicenter Italian Lung Cancer in the Elderly Study, which included 698 patients (median age 74 years), 7 found that single agent therapies were as effective as nonplatinum-based combination therapy, but with lower toxicity. Another trial, which compared a weekly docetaxel-cisplatin combination with tri-weekly docetaxel alone, did not show a survival benefit for doublet therapy. 8 Thus, the standard first-line treatment for elderly patients with advanced NSCLC remains unclear.
Despite the possible survival advantages of combination therapy in treating elderly patients with NSCLC, toxicity remains a major issue. 9 Due to a lack of subgroup analyses and insufficient clinical research data, the type of elderly patients who would benefit most from doublet chemotherapy are yet to be identified. Thus, the present meta-analysis was performed in an attempt to provide information regarding the optimum choice of chemotherapy for elderly patients with advanced NSCLC.
Patients and methods

Search strategy
An online literature search was performed using PubMed Õ , EMBASE and Cochrane databases for relevant articles updated to September 2012, using the following key words and various combinations: (non small cell OR adenocarcinoma OR squamous cell carcinoma) AND lung cancer; advanced; older OR elderly; first line; alone OR combination OR combined OR plus; versus OR vs OR comparing OR against. Papers and abstracts presented at the American Society of Clinical Oncology (updated to 2012), World Congress of Lung Cancer (updated to 2012), and European Society of Medical Oncology (updated to 2012) meetings were also searched. The language was restricted to English.
Eligibility criteria
Inclusion criteria for the manual selection of clinical trials comprised the following: (1) Patients diagnosed with advanced NSCLC that was previously untreated; (2) randomized controlled trials, involving patients aged >65 years, or including subgroup analysis of patients aged >65 years;
(3) comparisons between doublets and single agents as first-line treatment, using a third-generation cytotoxic drug; (4) at least one of the endpoints detailed in the data extraction section. No study authors were contacted for additional data, if relevant data were missing from the publication. All review articles, including systematic reviews and meta-analyses were excluded.
Data extraction and validity assessment
The quantitative 5-point Jadad scale 10 was used to assess the quality of included trials: trails with a score 2 were included for analyses. For analyses, the following data were extracted from eligible articles: median OS, overall response rate (ORR), 1-year survival rate (1-year SR), and percentage of patients experiencing grade 3-4 adverse events according to the National Cancer Institute Common Toxicity Criteria (NCICTC) version 2 or 3. 11 Data extraction was performed by two independent reviewers (S.F.W., Q.W.) who searched the literature and extracted the data independently. Any mismatches between reviewers were resolved by consensus after a re-check and discussion between the two reviewers.
Statistical analyses
The overall hazard ratio (HR) estimate was calculated for OS, and the risk ratio (RR) was calculated for ORR, 1-year SR, and grade 3-4 adverse events using Stata Õ software, version 11.0 (Stata Corp., College Station, TX, USA) for Windows Õ . 12 All statistical calculations (including graphical presentations and analyses) were performed as previously described, [13] [14] [15] using Stata Õ software. As for OS, all data including HR with 95% confidence intervals (CI) (lower limit [ll], upper limit [ul]) were used to evaluate the survival benefit for doublet compared with singleagent chemotherapy; this was extracted directly from papers included in the analysis, using the following code: 1) gen lnhr ¼ ln(hr) gen lnll ¼ ln(ll) gen lnul ¼ ln(ul); 2) metan lnhr lnll lnul, eform label(namevar ¼ study) xlabel(0.5,1,1.5) fixed/random effect(hr). For ORR, 1-year SR, and grade 3-4 adverse events, RR was calculated using the code: metan ncalive ncdeath ntalive ntdeath, label (namevar ¼ study, yearvar ¼ year) fixed/random rr counts.
Between-trial heterogeneity was estimated using the 2 -test-based Q-statistic and a P-value < 0.05 or I 2 > 50% was considered statistically significant. 16 If heterogeneity existed, data were analysed in a random-effects model; otherwise, a fixedeffects model was used. Sources of heterogeneity were assessed by subgroup stratification analysis based on several study characteristics including chemotherapy regimen and race. A statistical test with a P-value > 0.05 was considered significant. A HR> 1 reflected more deaths or a higher rate of disease progression in the doublet combination group, while a RR > 1 indicated a higher incidence of toxicityrelated adverse events or higher ORR in the doublet combination group. Publication bias was evaluated using the Begg's Funnel Plot and Egger's test. 17, 18 All P-values were two-sided. All confidence intervals (CIs) had a two-sided probability coverage of 95%.
Results
Study selection
The initial retrieval performed in September 2012 found 215 articles. After screening titles and abstracts, 175 articles did not meet the inclusion criteria; 38 full-text articles and two abstracts were reviewed for further inclusion. Subsequently, three articles were excluded due to lack of sufficient data for extraction, and 26 articles were excluded due to lack of elderly (>65 years) subgroup analyses. Eleven publications were finally included for analyses ( Figure 1 ; 13 trials and 2 782 patients. [5] [6] [7] [8] [19] [20] [21] [22] [23] [24] [25] All included trials, together with their related Jadad scale scores, are shown in Table 1 .
Publication bias
There was no obvious asymmetry revealed using Begg's Funnel Plot (P ¼ 0.246 for ORR) or Egger's Test (P ¼ 0.175 for OS; P ¼ 0.371 for 1-year SR; P ¼ 0.067 for ORR).
Overall survival
Overall survival was defined as time from randomization to death from any cause, censoring patients who had not died at the date last known alive. Pooled OS data available from 10 trials favoured doublet therapy, with a HR of 0.89 (95% CI 0.83, 0.95, P ¼ 0.001), using a random-effects model. Subgroup analysis based on chemotherapy regimens and race found that OS was significantly improved by platinumbased doublet therapy compared with single-agent therapy (HR 0.71, 95% CI 0.60, 0.84, P < 0.001), but there was no significant difference between nonplatinum based doublet therapy and single-agent therapy (HR 0.93, 95% CI 0.86, 1.01, P ¼ 0.078). In the East Asian subgroup, OS was not significantly improved by doublet therapy (HR 0.87, 95% CI 0.66, 1.16, P ¼ 0.336) but OS was improved by doublet therapy in the non-East Asian subgroup (HR 0.89, 95% CI 0.83, 0.95, P ¼ 0.001) ( Figure 2 ).
Survival at 1 year
Pooled RR based on data from nine trials for 1-year SR favoured doublet over singleagent therapy (RR 1.15, 95% CI 1.04, 1.28, P ¼ 0.007) using a random-effects model. Subgroup analysis showed that 1-year SR was significantly improved by platinumbased doublets (HR 1.28, 95% CI 1.11, 1.47, P ¼ 0.001), but not by nonplatinum single therapy (RR 1.06, 95% CI 0.90, 1.28, P ¼ 0.494).
Overall response rates
Overall response rates were defined as the sum of partial and complete response rates according to Response Evaluation Criteria in Solid Tumors (RECIST). 26 Pooled ORR based on data from 12 trials were significantly in favour of doublet therapy (RR 1.61, 95% CI 1.39, 1.86, P < 0.001), using a fixedeffects model. In addition, subgroup analysis based on chemotherapy regimens showed that platinum-based and nonplatinumbased regimens favoured doublet therapy in terms of ORR (RR 1.88, 95% CI 1.49, 2.38, P < 0.001; RR 1.46, 95% CI 1.21, 1.76, P < 0.001, platinum-based and nonplatinum based, respectively) compared with singleagent therapy. In the East Asian and non-East Asian populations, pooled ORR favoured doublet over single-agent therapy (RR 1.70, 95% CI 1.29, 2.23, P < 0.001; RR 1.58, 95% CI 1.33, 1.88, P < 0.001, East Asian and non-East Asian, respectively).
Safety
Adverse events were calculated according to the NCICTC (version 2 or 3). 11 Grade 3-4 toxicity was reported in 11 trials, with the doublet group having a significantly higher number of patients experiencing toxicity (anaemia, thrombocytopenia, fatigue) than the single-agent group. The non-East Asian population had more grade 3-4 toxicities with doublet therapy compared with single agents, however, the number of patients experiencing grade 3-4 thrombocytopenia and fatigue were similar for doublet and single agent therapy in the East Asian population ( Table 2 ).
Discussion
In the present meta-analysis, doubleagent chemotherapy was associated with significantly increased OS (HR 0.89, 95% CI 0.83, 0.95, P ¼ 0.001), 1-year SR (RR 1.15, 95% CI 1.04, 1.28, P ¼ 0.007), and ORR (RR 1.61, 95% CI 1.39, 1.86, P < 0.001) compared with single agents. Subgroup analysis showed OS and 1-year SR were significantly improved by platinum-based doublets but not by nonplatinum-based doublets compared with single-agent therapy. Unlike the non-Asian population, however, no significantly increased benefit regarding OS or 1-year SR was associated with doublet therapy in the Asian population. Notably, in the East Asian population, grade 3-4 thrombocytopenia and fatigue were similar with doublet and single-agent therapy. In the non-East Asian population, the incidence of toxicityrelated fatigue, thrombocytopenia and anaemia were significantly more frequent with double-compared with single-agent therapy.
In the present study, platinum-based doublet therapy appeared to be more efficacious than single third-generation agents, and the non-Asian population was associated with a greater benefit from doubletagent versus single-agent therapy compared with the Asian population. Even with singleagent therapy, elderly Asians experienced serious adverse events that were not significantly different compared with double-agent therapy. Severe adverse effects are directly associated with poor health-related qualityof-life and psychological burden. 27 In the present meta-analysis, the incidence of serious adverse events may be the reason why double-agent therapy was not associated with survival benefits in the Asian population.
The results of the present systematic review and meta-analysis should be interpreted with caution, since: (1) The definition of older patients was not clearly established.
In previous studies, a cut off has been set at 65 years of age, particularly in epidemiological studies, but this is problematic as the median age of lung cancer diagnosis is 70-71 years. 19, 28 The cut off for entry into therapeutic trials is usually 70 years of age, probably because treatment may not require age-related adaptation before this age cut off; 19, 28 (2) The treatment schedules differed between the included trials. Because of these limitations it could not be concluded that platinum-based doublet therapy should be considered as first-line treatment in patients aged >70 years of age. (3) The results of the present systematic review may be influenced by four large trials, 7, 8, 19, 22 which may be responsible for the lack of survival benefit seen in East Asian patients. It is possible that even after pooling the data, the power may have been inadequate to detect a difference. Thus, further high-quality, randomized controlled trials are warranted to clarify the efficacy of doublet versus singleagent therapy as first line treatment in clearly defined elderly patients.
In conclusion, doublet therapy was superior to single third-generation cytotoxic agents as first-line treatment for elderly patients with advanced NSCLC, when patients were observed to tolerate anaemia, thrombocytopenia and fatigue. There was evidence from the present meta-analysis to suggest that race may be a factor for consideration when choosing double-agent or single-agent therapy as first line treatment of NSCLC in the elderly.
